AzTrials
AzTrials

ACL InjuryBFRNCT03794570

BFR Therapy After ACL Reconstruction

A study testing Blood flow restriction therapy - with Delfi Personalized Tourniquet System in people with ACL Injury and Quadriceps Muscle Atrophy, run by Steadman Philippon Research Institute at 1 site in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

This study is a prospective, double-blinded, randomized control trial examining the effect of blood flow restriction (BFR) therapy on reducing post-operative quadriceps atrophy in patients undergoing anterior cruciate ligament reconstruction (ACLR). Read more about this study

Who is it for?
Ages 14 to 70 years
Conditions the study is for
ACL Injury, Quadriceps Muscle Atrophy
What is being tested?
Blood flow restriction therapy - with Delfi Personalized Tourniquet System
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
0 participants
Where
1 siteUnited States
Study dates
18 Dec 2018to 1 Jun 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 14 to 70 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Age 14-70
  • Undergoing ACL reconstruction with patellar tendon autograft
  • Full weightbearing after surgery
  • Surgery performed within 14 days of ACL injury
  • No nerve catheter in place

Who cannot join

  • Meniscal root tears
  • radial meniscal tears
  • multi-ligament knee injury
  • revision ACL reconstruction
  • concomitant osteotomies
  • concomitant cartilage resurfacing procedures
Show all 15Show fewer
  • fracture preventing full-weightbearing of operated extremity
  • previous history of deep vein thrombosis (DVT)
  • new nerve injury/findings affecting operative extremity
  • active femoral nerve catheter
  • nerve block lasting longer than day of surgery
  • patients unable to tolerate BFR treatment
  • untolerable post-operative pain due to absence of nerve catheter
  • proximal thigh girth greater than 34cm
  • time to surgery greater than 14 days

Trial locations and contacts

1 site in 1 country.

United States1 site
  • The Steadman Clinic

    Vail, Colorado, 81657

Other trials in United States

About this study

Official title: Blood Flow Restriction Therapy to Prevent Muscle Atrophy Following Anterior Cruciate Ligament Reconstruction

This study is a prospective, double-blinded, randomized control trial examining the effect of blood flow restriction (BFR) therapy on reducing post-operative quadriceps atrophy in patients undergoing anterior cruciate ligament reconstruction (ACLR). Following ACLR, patients will undergo a rehabilitation protocol either w/ BFR therapy or sham BFR therapy.

Read the detailed description

Patients will be randomized to either BFR therapy or no BFR therapy. Randomization will be carried out using block randomization with blocks of 6.

Those undergoing BFR therapy will have a Delfi Personalized Tourniquet System (PTS) cuff applied to the proximal thigh of their operative leg and inflated to 80% limb occlusive pressure (LOP) calculated by the Delfi PTS device during physical therapy (PT) sessions from day 2 after surgery through day 7 after surgery. Those in the no BFR group will have the Delfi PTS cuff applied to their proximal thigh with inflation of the tourniquet to minimal pressure only. BFR therapy will be administered by health care providers who have undergone training and certification for BFR therapy with the Delfi PTS device.

Both groups will undergo the following PT regimen two times daily beginning on the day after the surgical procedure and lasting for 6 weeks post-operatively:

  • Quad sets = x1 min isometric hold, 30 sec off, 3 sets
  • Terminal knee extensions = 3x15, 30 sec rest or short arc quads sitting 1 x 30 + 3 x 15, 30 sec rest
  • Once range of motion (ROM) allows: Bike 10 mins, low to no resistance

Each physical therapy visit will last approximately 60 minutes. During that time, there will be a total estimated time of 5-7 minutes during which the tourniquet cuff will be on the thigh, and the tourniquet will be inflated for a similar time period. The tourniquet will inflate for about 1 minute in order to find out the specific pressure for the patient's leg and then will remain inflated until exercises are completed, which should take 4-6 minutes. The cuff will then be deflated and is removed from the leg within about 30 seconds of being deflated.

Patients will have MRI performed pre-operatively and at 6 weeks post-operatively with axial cuts to 50% femoral length above joint line. Quadriceps cross-sectional area will be measured by a blinded observer using MRI. Patients will have clinical measurements including thigh girth, Lachman test, knee joint range of motion, and knee joint swelling performed pre-operatively, at post-op day 1, post-op day 14, and 6 weeks post-operatively. All clinical measurements will be performed by a blinded observer. Additionally, patient reported pain level will be obtained at the same timepoints in which clinical measurements are performed using visual analog scale.

In order to ensure there are no nerve injuries present in patients prior to undergoing application and inflation of thigh tourniquet, all patients in the study will have single shot adductor and/or sciatic nerve blocks to ensure 24 hour period without nerve block prior to initiation of BFR therapy. Patients included in the study cannot have a nerve block lasting longer than the day of surgery. To ensure no new nerve deficits are present, the patients will undergo a physical examination during morning rounding on post-operative day 1 to assess for new nerve deficits.

Being tested
Blood flow restriction therapy - with Delfi Personalized Tourniquet System, Sham blood flow restriction therapy - with Delfi Personalized Tourniquet System
Medical subject headings
Anterior Cruciate Ligament Injuries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Blood flow restriction therapy - with Delfi Personalized Tourniquet SystemDevice

    Physical therapy performed with Blood flow restriction therapy tourniquet inflated to 80% limb occlusion pressure

  • Sham blood flow restriction therapy - with Delfi Personalized Tourniquet SystemDevice

    Physical therapy performed with Blood flow restriction therapy tourniquet inflated to only minimal pressure

Study groups in NCT03794570
Study groupRoleWhat they receive
ControlSham comparatorPatients in this group will have BFR tourniquet applied but inflated to only minimal pressure.
Receives: Device: Sham blood flow restriction therapy - with Delfi Personalized Tourniquet System
Blood Flow Restriction (BFR) TherapyExperimentalPatients in this group will have BFR tourniquet applied and inflated to 80% limb occlusion pressure
Receives: Device: Blood flow restriction therapy - with Delfi Personalized Tourniquet System

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Quadriceps Cross-Sectional Area

    Change in quadriceps cross-sectional area measured on MRI pre-operatively compared to post-operatively

    Measured: Pre-op and 6-weeks post-operative

Secondary outcomes (3)
  1. Numeric rating scale pain

    Patient reported pain levels using numeric rating scale (NRS) on a scale of 1-10 where 10 represents maximal pain and 1 represents minimal pain

    Measured: Days 1, 14, and 6 weeks after surgery

  2. Thigh girth

    Measured thigh girth 15cm above knee joint line

    Measured: Days 1, 14, and 6 weeks after surgery

  3. Knee joint range of motion

    Measure knee range of motion

    Measured: Days 1, 14, and 6 weeks after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jan 2019
  2. Study start18 Dec 2018
  3. Primary completion1 Jun 2019
  4. Study completion1 Jun 2019

Why it stopped: Investigator separated from institution

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Double blinded randomized control trial
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03794570
Sponsor's protocol ID
2018-35
Acronym
BFR
Status last verified
Dec 2019
First submitted
20 Dec 2018
Last updated
4 Dec 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No: No sharing

Questions about this trial

What is this clinical trial studying?

A study testing Blood flow restriction therapy - with Delfi Personalized Tourniquet System in people with ACL Injury and Quadriceps Muscle Atrophy, run by Steadman Philippon Research Institute at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 4 Dec 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Quadriceps Cross-Sectional Area (time frame: Pre-op and 6-weeks post-operative). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2019; AzTrials last refreshed its copy on 28 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in